Skip to main content
OpenTrials
Completed

NCT Number: NCT03399396

Increasing HPV Vaccination in Community-Based Pediatric Practices

The central goal of this study is to identify the optimal approach to implementing an evidence-based practice facilitation (PF) intervention for the uptake and completion of HPV vaccine among adolescents receiving care in the community, guided by implementation science theory.

AIM 1: Determine the clinical effectiveness and cost-effectiveness of two modalities for delivering a multi-component PF intervention to increase HPV vaccination initiation and completion in community-based pediatric practices. The investigators will compare the traditional In-person Coaching PF modality to a lower-resource Web-Based Coaching PF modality. The primary patient outcome is HPV vaccination. The investigators will also examine and compare the sustainability of practice changes on vaccination rates and the effects over time for each intervention modality.

AIM 2. Understand mechanisms of why the PF intervention may work better for some pediatric practices than others for HPV vaccination. The investigators will examine theory-based determinants at the organizational, provider, and patient levels that may mediate (explain) or moderate (change) the effects of the PF intervention on vaccination outcomes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Vanderbilt University Medical Center

Nashville, Tennessee, 37203, United States

About this study

Background:

The human papillomavirus (HPV) vaccine offers the unprecedented opportunity to prevent nearly all cervical and anal cancers and a high proportion of vaginal, oropharyngeal, vulvar and penile cancers, where HPV is the etiologic agent. HPV vaccination is recommended for all children ages 11-12, with catch up for females to age 26 and males to age 21. However, despite clear and indisputable value in cancer prevention, uptake and completion of the HPV vaccine series has lagged far behind the goal of 80%. Provider recommendation is the strongest determinant of HPV vaccination, but slow translation of guidelines for preventive services, such as immunizations, into practice is a known challenge. Practice Facilitation (PF), also called quality improvement coaching, is a multicomponent quality improvement intervention approach that has well-established efficacy, in which external support and resources are provided to build the internal capacity of practices to improve quality of care and patient outcomes.

Objectives:

The central goal of the study is to identify the optimal approach to implementing an evidence-based intervention for the uptake and completion of HPV vaccine among adolescents receiving care in the community, guided by implementation science theory.

AIM 1: Determine the clinical effectiveness and cost-effectiveness of two modalities for delivering a multi-component PF intervention to increase HPV vaccination initiation and completion in community-based pediatric practices.

The investigators will compare the traditional In-person Coaching modality to a lower-resource Web-Based Coaching modality. The primary patient outcome is HPV vaccination. The investigators will also examine and compare the sustainability of practice changes on vaccination rates and the effects over time for each intervention modality.

H1: Both interventions will result in significant increases in HPV vaccination from baseline over time.

H2: Increases in the rate of HPV vaccination will be higher and sustained for a longer period of time in the In-person Coaching PF Arm as compared with the Web-Based Coaching Arm.

H3: The Web-Based Coaching Arm will be more cost-effective than the In-person Coaching Arm.

AIM 2. Understand mechanisms of why the PF intervention may work better for some pediatric practices than others for HPV vaccination.

The investigators will examine theory-based determinants at the organizational, provider, and patient levels that may mediate (explain) or moderate (change) the effects of the PF intervention on vaccination outcomes.

H4: Adoption of changes (process variables) and patient factors will mediate effects of the intervention on HPV vaccination outcomes.

H5: Organizational factors, provider attitudes, and intervention characteristics will moderate intervention effects on HPV vaccination outcomes.

Implications:

The findings will inform organizations about which PF modality to use among their constituent practices to improve HPV vaccination rates, with potential for future national dissemination.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All providers and staff at each practice

Exclusion criteria

  • None

Treatment and study plan

Practice facilitation for HPV vaccine

Behavioral

The practice facilitation intervention provides coaching support to pediatric practices to guide them through quality improvement projects to increase HPV vaccination rates.

Primary outcomes

  1. Age-appropriate completion rate (ages 13-17)

    Time frame: Annually, up to 3 years post baseline

    Percentage of active patients ages 13-17 who completed the HPV vaccine series before 13th birthday

Secondary outcomes

  1. Age-appropriate initiation rate (ages 13-17)

    Time frame: Monthly, up to 36 months post baseline

    Percentage of active patients ages 13-17 who received at least one dose of HPV vaccine before 13th birthday

  2. Age-appropriate completion rate (at age 13)

    Time frame: Monthly, up to 36 months post baseline

    Percentage of active patients who turned age 13 who completed the HPV vaccine series before 13th birthday

  3. Age-appropriate initiation rate (at age 13)

    Time frame: Monthly, up to 36 months post baseline

    Percentage of active patients who turned age 13 who received at least one dose of HPV vaccine before 13th birthday

  4. Overall completion rate (ages 13-17)

    Time frame: Monthly, up to 36 months post baseline

    Percentage of active patients ages 13-17 who completed the HPV vaccine series at any age

  5. Overall initiation rate (ages 13-17)

    Time frame: Monthly, up to 36 months post baseline

    Percentage of active patients ages 13-17 who received at least one dose of HPV vaccine at any age

  6. Dose received rate (well visits)

    Time frame: Monthly, up to 36 months post baseline

    Percentage of well visits in which a dose of HPV vaccine was administered (1st, 2nd, or 3rd dose), among all well visits for active vaccine-eligible patients ages 11-17

  7. Dose received rate (all visits)

    Time frame: Monthly, up to 36 months post baseline

    Percentage of visits in which a dose of HPV vaccine was administered (1st, 2nd, or 3rd dose), among all visits for active vaccine-eligible patients ages 11-17

  8. Age at vaccination

    Time frame: Monthly, up to 36 months post baseline

    Average age at receipt of first HPV vaccine dose, among active patients ages 13-17 who received 1st dose

  9. Time to series completion

    Time frame: Monthly, up to 36 months post baseline

    Average number of months from 1st dose to last dose of HPV vaccine, among active patients ages 13-17 who completed the series

Other outcomes

  1. Documented recommendation rate (well visits)

    Time frame: Monthly, up to 36 months post baseline

    Percentage of well visits with documentation of HPV vaccine either administered, deferred or refused, among all well visits for active vaccine-eligible patients ages 11-17

  2. Documented recommendation rate (all visits)

    Time frame: Monthly, up to 36 months post baseline

    Percentage of visits with documentation of HPV vaccine either administered, deferred or refused, among all visits for active vaccine-eligible patients ages 11-17

  3. Bundling adolescent vaccines rate

    Time frame: Monthly, up to 36 months post baseline

    Percentage of visits in which HPV, meningococcal, and Tdap vaccines were administered, among all visits for active patients ages 11-12 in which Tdap was administered and patient was eligible for both HPV and meningococcal vaccines

  4. Missed opportunities rate

    Time frame: Monthly, up to 36 months post baseline

    Percentage of non-well visits in which HPV vaccine was not administered, among all visits for active vaccine-eligible patients ages 11-17

Sponsors and collaborators

Lead sponsor

Pamela Hull

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
Jan 16, 2018
Registry last updated
Dec 5, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.